Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.44 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 8/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 8/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.38 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.37 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.37 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.37 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6374773 | 0.99 | USP2 (0.43) | PDE4DPDE7AUSP2CSNK2A2CSNK2A1 | |
| SCHEMBL6132560 | 0.91 | PDE4D (0.48) | PDE4DPDE7AUSP2HRH3 | |
| SCHEMBL6376063 | 0.90 | PDE4D (0.46) | PDE4DPDE7AUSP2CSNK2A2CSNK2A1 | |
| SCHEMBL13099171 | 0.88 | USP2 (0.52) | PDE4DUSP2CHEK1IP6K1IP6K3 | |
| SCHEMBL6134823 | 0.88 | HRH3 (0.38) | PDE4DPDE7AUSP2HRH3 | |
| SCHEMBL6132812 | 0.86 | HRH3 (0.38) | PDE4DPDE7AUSP2HRH3 | |
| SCHEMBL6132815 | 0.85 | ALDH1A1 (0.41) | USP2HRH3 | |
| SCHEMBL13098814 | 0.84 | HRH3 (0.39) | USP2HRH3 | |
| SCHEMBL6134549 | 0.83 | KDM4E (0.43) | HRH3 | |
| SCHEMBL13098918 | 0.83 | MAPT (0.35) | PDE4DPDE7AUSP2CSNK2A2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6884774-B2 | Cyclic hexapeptide derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| EP-1259535-B1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-04-13 | — | — | EP | disclosed |
| US-20030083238-A1 | Cyclic hexapeptide derivatives | ASTELLAS PHARMA INC. (JP) | 2003-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083238-A1 | Cyclic hexapeptide derivatives | NGLY1, ALG1, CHIT1 | PDE4D 1912/4885PDE7A 670/4885USP2 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.